![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment make... Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%. Show more
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES PR Newswire MINNEAPOLIS, May 31, 2024 MINNEAPOLIS, May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that...
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE PR Newswire MINNEAPOLIS, May 30, 2024 MINNEAPOLIS, May 30, 2024 /PRNewswire/ -- Bio-Techne...
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing PR Newswire ST. PAUL, Minn., May 29, 2024 ST. PAUL, Minn...
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE PR Newswire MINNEAPOLIS, May 23, 2024 MINNEAPOLIS, May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:...
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY PR Newswire MINNEAPOLIS, May 22, 2024 MINNEAPOLIS...
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024 PR Newswire MINNEAPOLIS, May 8, 2024 MINNEAPOLIS, May 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today...
BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) PR Newswire MINNEAPOLIS, May 7, 2024 MINNEAPOLIS, May 7, 2024 /PRNewswire/...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.84 | -3.71241830065 | 76.5 | 77.02 | 73.43 | 873168 | 74.89748808 | CS |
4 | -7.18 | -8.88174171202 | 80.84 | 81.029 | 73.43 | 848456 | 77.18118176 | CS |
12 | 2.91 | 4.11307420495 | 70.75 | 85.57 | 61.16 | 1037384 | 73.57528214 | CS |
26 | -3.12 | -4.06355821829 | 76.78 | 85.57 | 61.16 | 1045254 | 72.57202492 | CS |
52 | -3.3 | -4.28794178794 | 76.96 | 89.91 | 51.79 | 1030105 | 71.54609533 | CS |
156 | -34.415 | -31.8436271108 | 108.075 | 135.9625 | 51.79 | 654317 | 79.68808163 | CS |
260 | 20.195 | 37.7723744506 | 53.465 | 135.9625 | 38.7925 | 466978 | 77.96253769 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions